Premium
Tailored Doxorubicin‐ H yaluronan Conjugate as a Potent Anticancer Glyco‐ D rug: An Alternative to Prodrug Approach
Author(s) -
Oommen Oommen P.,
Garousi Javad,
Sloff Marije,
Varghese Oommen P.
Publication year - 2014
Publication title -
macromolecular bioscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 105
eISSN - 1616-5195
pISSN - 1616-5187
DOI - 10.1002/mabi.201300383
Subject(s) - doxorubicin , conjugate , cytotoxicity , chemistry , prodrug , cd44 , drug delivery , cancer cell , pharmacology , biochemistry , cancer , cell , biology , in vitro , chemotherapy , mathematical analysis , genetics , mathematics , organic chemistry
Releasibility of doxorubicin from drug‐conjugates is believed to be a prerequisite for its anti‐cancer activity. Here, a new glyco‐drug approach that circumvents the releasibility restriction is reported, opening a new possibility to design efficient, target specific drug delivery system. It is discovered that stable amide coupling of doxorubicin (DOX) tohyaluronan (HA) shows dose dependent cytotoxicity to CD44 positive human coloncancer cells (HCT116) as compared to human breast cancer cells(MCF‐7) and mouse fibroblast cells (NIH‐3T3), which express less CD44 receptor. This direct conjugation approach is an easy scalable strategy that could be adopted to design innocuous anti‐tumor nanoparticle formulations.